Gena Wang
Stock Analyst at Barclays
(2.10)
# 2,666
Out of 4,831 analysts
207
Total ratings
35.56%
Success rate
-6.07%
Average return
Main Sectors:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLLS Cellectis | Maintains: Overweight | $5 → $4 | $1.43 | +179.72% | 4 | May 13, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $56 → $42 | $36.69 | +14.47% | 16 | May 9, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Overweight | $45 → $38 | $3.31 | +1,048.04% | 2 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $56 → $42 | $45.90 | -8.50% | 15 | May 8, 2025 | |
| CYTK Cytokinetics | Maintains: Overweight | $55 → $53 | $30.73 | +72.47% | 2 | May 8, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Equal-Weight | $8 → $11 | $10.08 | +9.13% | 10 | May 7, 2025 | |
| BEAM Beam Therapeutics | Maintains: Equal-Weight | $31 → $25 | $17.94 | +39.35% | 9 | May 7, 2025 | |
| MRNA Moderna | Maintains: Equal-Weight | $45 → $40 | $25.40 | +57.48% | 9 | May 2, 2025 | |
| BLUE bluebird bio | Maintains: Overweight | $40 → $8 | $3.20 | +150.00% | 11 | Mar 31, 2025 | |
| RNA Avidity Biosciences | Maintains: Overweight | $63 → $57 | $28.83 | +97.71% | 2 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $5.01 | +518.76% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $26 | $8.22 | +216.30% | 7 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $435 → $467 | $433.00 | +7.85% | 16 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $1.47 | +104.08% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $3 → $4 | $3.99 | +0.25% | 8 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $9 | $0.45 | +1,899.11% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $295 → $329 | $265.75 | +23.80% | 7 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $86 | $59.87 | +43.64% | 15 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $15 | $2.72 | +451.47% | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $226 → $203 | $35.94 | +464.83% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $50 | $8.32 | +500.96% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $81 | $35.49 | +128.23% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $45 → $51 | $32.78 | +55.58% | 9 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $94 | $31.90 | +194.67% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $11.64 | -22.68% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $12.45 | +100.80% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $5.33 | +238.03% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $8 | $8.01 | -0.12% | 1 | Nov 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $2.95 | +205.08% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $5.62 | +4,793.24% | 1 | Jan 6, 2017 |
Cellectis
May 13, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $1.43
Upside: +179.72%
CRISPR Therapeutics AG
May 9, 2025
Maintains: Equal-Weight
Price Target: $56 → $42
Current: $36.69
Upside: +14.47%
4D Molecular Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $45 → $38
Current: $3.31
Upside: +1,048.04%
PTC Therapeutics
May 8, 2025
Maintains: Equal-Weight
Price Target: $56 → $42
Current: $45.90
Upside: -8.50%
Cytokinetics
May 8, 2025
Maintains: Overweight
Price Target: $55 → $53
Current: $30.73
Upside: +72.47%
BioCryst Pharmaceuticals
May 7, 2025
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $10.08
Upside: +9.13%
Beam Therapeutics
May 7, 2025
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $17.94
Upside: +39.35%
Moderna
May 2, 2025
Maintains: Equal-Weight
Price Target: $45 → $40
Current: $25.40
Upside: +57.48%
bluebird bio
Mar 31, 2025
Maintains: Overweight
Price Target: $40 → $8
Current: $3.20
Upside: +150.00%
Avidity Biosciences
Feb 28, 2025
Maintains: Overweight
Price Target: $63 → $57
Current: $28.83
Upside: +97.71%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $5.01
Upside: +518.76%
Feb 28, 2025
Maintains: Overweight
Price Target: $55 → $26
Current: $8.22
Upside: +216.30%
Feb 11, 2025
Maintains: Equal-Weight
Price Target: $435 → $467
Current: $433.00
Upside: +7.85%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $1.47
Upside: +104.08%
Nov 15, 2024
Maintains: Underweight
Price Target: $3 → $4
Current: $3.99
Upside: +0.25%
Nov 14, 2024
Maintains: Overweight
Price Target: $3 → $9
Current: $0.45
Upside: +1,899.11%
Nov 1, 2024
Maintains: Overweight
Price Target: $295 → $329
Current: $265.75
Upside: +23.80%
Oct 4, 2024
Maintains: Overweight
Price Target: $110 → $86
Current: $59.87
Upside: +43.64%
Aug 14, 2024
Maintains: Overweight
Price Target: $18 → $15
Current: $2.72
Upside: +451.47%
Aug 8, 2024
Maintains: Overweight
Price Target: $226 → $203
Current: $35.94
Upside: +464.83%
Aug 5, 2024
Maintains: Overweight
Price Target: $55 → $50
Current: $8.32
Upside: +500.96%
Aug 5, 2024
Maintains: Overweight
Price Target: $83 → $81
Current: $35.49
Upside: +128.23%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $45 → $51
Current: $32.78
Upside: +55.58%
Jan 24, 2024
Maintains: Overweight
Price Target: $93 → $94
Current: $31.90
Upside: +194.67%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $11.64
Upside: -22.68%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $12.45
Upside: +100.80%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $5.33
Upside: +238.03%
Nov 17, 2021
Maintains: Overweight
Price Target: $24 → $8
Current: $8.01
Upside: -0.12%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $2.95
Upside: +205.08%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $5.62
Upside: +4,793.24%